A Phase 1 interventional study of Pevonedistat 25 mg/m^2 and Pevonedistat 44 mg/m^2 in Leukemia, Myeloid, Acute and Myelodysplastic Syndromes, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing pevonedistat in Leukemia, Myeloid, Acute — 1 open to participants now, 4 under way, 2 of them phase 3. pevonedistat · Leukemia, Myeloid, Acute.
Among the 17 studies testing pevonedistat in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 3 that started in 2016, is one of 9 in phase 1, and was the 4th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →1 of the 17 studies testing pevonedistat in Leukemia, Myeloid, Acute is open now, in 1 country. Recruiting first, the newest first:
Beat AML, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 2
First in 2009; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 23 across the 17 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
14 studies in Leukemia, Myeloid, Acute by Takeda: none open now, none under way, none of them phase 3. Of 13 finished, 8 (62%) have results posted.
Among the 14 studies in Leukemia, Myeloid, Acute by Takeda, this one is the 10th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 7 in phase 1, and was the 10th registered.
Takeda’s Leukemia, Myeloid, Acute studies by the year they started, since 1997.
2 of the studies testing pevonedistat in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03330821University of Southern CaliforniaPevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing pevonedistat in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 14 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of pevonedistat administered as a single agent and in combination with azacitidine in adult east Asian participants with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
The drug being tested in this study is called Pevonedistat. Pevonedistat is being tested to treat people with myelodysplastic syndromes MDS (including nonproliferative chronic myelomonocytic leukemia [CMML]) and AML (acute myeloid leukaemia) as a single-agent and in combination treatment with azacitidine. This study will look at the safety and tolerability, the recommended phase 2/phase 3 dose of pevonedistat administered in combination with azacitidine, pharmacokinetics and response to treatment in participants who take single agent pevonedistat compared to participants who take pevonedistat and azacitidine.
The study will enroll approximately 37 participants. Participants will be assigned into one of the four treatment groups which will remain disclosed to the patient and study doctor during the study. Participants will be first enrolled at single-agent low dose level (25 mg/m\^2). If this dose is tolerable, participants will be enrolled in parallel at single-agent higher dose level (44 mg/m\^2) and in combination treatment cohorts.
This multi-center trial will be conducted in Japan, Korea and Taiwan. The overall time to participate in this study is approximately 24 months. Participants will attend the End of Study (EOS) visit for safety, 30 days after receiving their last dose of study drug or before the start of subsequent antineoplastic therapy (other than hydroxyurea).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
East Asian patients aged 18 years or older (or minimum age of legal consent consistent with local regulations) when written study is obtained must meet 1 of the following diagnosis criteria for either the Single-Agent Arm or the Combination Arm (additional restrictions apply to the Single Agent Arm):
a. Are male and female participants with WHO-defined AML, including leukemia secondary to prior chemotherapy or resulting from an antecedent hematologic disorder, who have failed to achieve CR or who have after prior therapy (R/R) and are not candidates for potentially curative treatment, or ii. Are male and female participants aged 60 years or older with previously untreated AML who have bone marrow blasts \<30% and who are not candidates for standard induction chemotherapy, or iii. Are male and female participants with WHO-defined MDS that meets the IPSS-R criteria for the very high, high, or intermediate risk group, for whom standard curative, life-prolonging treatment does not exist or is no longer effective (R/R), or iv. Are male and female participants with previously untreated MDS that meets the IPSS-R criteria for the very high, high, or intermediate risk group, or vi. Are male and female participants with WHO-defined CMML-2 or CMML-1 that meets the IPSS-R criteria for the very high, high, or intermediate risk group CMML-1 participants must have bone marrow blasts >=5%
Exclusion Criteria include, in part:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pevonedistat, 25 milligram per square meter (mg/m\^2), 60-minute infusion, intravenously, on Days 1, 3 and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
Drug: Pevonedistat 25 mg/m^2
Pevonedistat, 44 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5, followed by a rest period of 16 days, in 21-day treatment cycles.
Drug: Pevonedistat 44 mg/m^2
Pevonedistat 10 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
Drug: Pevonedistat 10 mg/m^2 · Drug: Azacitidine 75 mg/m^2
Pevonedistat 20 mg/m\^2, 60-minute infusion, intravenously, on Days 1, 3, and 5 and azacitidine 75 mg/m\^2, on Days 1 to 5, and Days 8 and 9, intravenously or subcutaneously, followed by a rest period of 19 days, in 28-day treatment cycles.
Drug: Pevonedistat 20 mg/m^2 · Drug: Azacitidine 75 mg/m^2
Drug page: Pevonedistat
Pevonedistat 25 mg/m\^2 intravenous infusion.
Drug page: Pevonedistat
Pevonedistat 44 mg/m\^2 intravenous infusion.
Drug page: Pevonedistat
Pevonedistat 10 mg/m\^2 intravenous infusion.
Drug page: Pevonedistat
Pevonedistat 20 mg/m\^2 intravenous infusion.
Drug page: Azacitidine
Azacitidine 75 mg/m\^2 intravenous or subcutaneous formulation.
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From first dose through 30 days after the last dose of study drug: single agent arms (up to Cycle 19 [up to Day 429]) (Cycle=21 days); combination arms (up to Cycle 65 [up to Day 1850]) (Cycle=28 days)
Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1
DLT: Any of following events considered possibly related to study drug(s) by investigator: Grade (G) 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis; G3 diarrhea occurred despite maximal supportive therapy; G3 arthralgia/myalgia despite use of optimal analgesia; G3 nonhematologic toxicity with exceptions: 1) Brief fatigue, 2) hypophosphatemia; Persistent elevations of transaminases/bilirubin above G2 beyond 2 days between doses; Other study drug-related nonhematologic toxicities G2 or greater, required a dose reduction/discontinuation of pevonedistat. G3 or greater hematologic toxicities, including G3 or 4 febrile neutropenia, considered DLTs if: A delay in initiation of Cycle 2 due to lack of adequate recovery from treatment-related toxicity: 1) Of more than (\>) 4 weeks due to hematologic toxicity believed not related to leukemic infiltration. Bone marrow (BM) evaluation may have been required. 2) Of \>2 weeks due to nonhematologic toxicities.
Time frame: Cycle 1 (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Number of Participants With Clinically Significant Abnormal Laboratory Values
Time frame: Baseline up to Cycle 19 (up to Day 399) in single agent arms (Cycle=21days) and Cycle 65 (up to Day 1820) in combination arms (Cycle=28 days)
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
Time frame: Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1
Time frame: Cycle 1 Day 1: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5
Time frame: Cycle 1 Day 5: pre-infusion and at multiple time points (up to 48 hours) post-infusion (Cycle length = 21 days [single agent arms]; 28 days [combination arms])
Overall Response Rate (ORR) for Participants With AML
ORR for AML was defined as the percentage of participants with a complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR) based on Modified International Working Group (IWG) Response Criteria for AML. CR was defined as participant achieved the morphologic leukemia-free state and had an absolute neutrophil count (ANC) of more than 1,000 per microliter (/mcL) and platelets of greater than or equal to (\>=) 100,000/mcL. A morphologic leukemia-free state requires less than (\<) 5 percent (%) blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CRi was, after chemotherapy, some participants who fulfilled all of the criteria for CR except for residual neutropenia (\<1,000/mcL) or thrombocytopenia (\<100,000/mcL). PR designation required all the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to between 5% and 25% in the bone marrow aspirate.
Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
ORR for Participants With MDS
ORR for MDS: Percentage of participants with CR,PR or hematologic improvement(HI) based on IWG Response Criteria. CR: BM:\<=5% myeloblasts with normal maturation of all cell lines; persistent dysplasia noted peripheral blood: hemoglobin (Hgb)\>=11 gram per deciliter (g/dL),platelets\>=100\*10\^9/L,neutrophils \>=1.0\*10\^9/L, blasts 0%. PR:CR criteria if abnormal before treatment except: BM blasts decreased by \>=50% from pretreatment but still\>5%; cellularity, morphology not relevant. HI criteria: Erythroid response:Hgb up by \>=1.5 g/dL; transfused RBC reduced by at least 4 red blood cell (RBC) transfusions/8 weeks comparatively last 8 weeks; Platelet response: Increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets; increase from \<20\*10\^9/L to \>20\*10\^9/L and by 100%; Neutrophil response: At least 100% and absolute increase \>0.5\*10\^9/L; Progression/relapse after HI: Granulocytes/platelets decreased by 50% from maximum; Hgb reduced by \>=1.5 g/dL; transfusion dependence.
Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Percentage of Participants With CR for Participants With AML
CR was defined as participant achieved the morphologic leukemia-free state and had an ANC of more than 1,000/mcL and platelets of \>=100,000/mcL. A morphologic leukemia-free state requires \<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CR assessment was based on IWG Response Criteria.
Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Percentage of Participants With CR for Participants With MDS
CR was defined as participant with bone marrow: less than or equal to (\<=) 5% myeloblasts with normal maturation of all cell lines; persistent dysplasia was noted peripheral blood: Hgb \>=11 g/dL, platelets \>=100\*10\^9/L, neutrophils \>=1.0\*10\^9 per liter (/L), blasts 0%. CR assessment was based on IWG Response Criteria.
Time frame: From first dose up to 30 days after last dose of study drug or before start of subsequent antineoplastic therapy, whichever comes earlier up to Cycle 19 (up to Day 429, single agent)(Cycle=21 days) and Cycle 65 (up to Day 1850, combination)(Cycle=28 days)
Participants took part in the study at 8 investigative sites in Japan, Taiwan and South Korea from 16 May 2016 to 25 January 2022.
| Milestone | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Started | 3 | 7 | 3 | 10 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 7 | 3 | 10 |
| Withdrew: Progressive disease | 2 | 5 | 0 | 4 |
| Withdrew: Adverse event | 0 | 2 | 2 | 3 |
| Withdrew: Other | 0 | 0 | 1 | 1 |
| Withdrew: Initiation of hematopoietic stem cell transplant | 0 | 0 | 0 | 1 |
| Withdrew: Symptomatic deterioration | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| TEAEs | 3 | 7 | 3 | 10 |
| SAEs | 2 | 7 | 3 | 6 |
DLT: Any of following events considered possibly related to study drug(s) by investigator: Grade (G) 3 or greater nausea and/or emesis despite use of optimal antiemetic prophylaxis; G3 diarrhea occurred despite maximal supportive therapy; G3 arthralgia/myalgia despite use of optimal analgesia; G3 nonhematologic toxicity with exceptions: 1) Brief fatigue, 2) hypophosphatemia; Persistent elevations of transaminases/bilirubin above G2 beyond 2 days between doses; Other study drug-related nonhematologic toxicities G2 or greater, required a dose reduction/discontinuation of pevonedistat. G3 or greater hematologic toxicities, including G3 or 4 febrile neutropenia, considered DLTs if: A delay in initiation of Cycle 2 due to lack of adequate recovery from treatment-related toxicity: 1) Of more than (\>) 4 weeks due to hematologic toxicity believed not related to leukemic infiltration. Bone marrow (BM) evaluation may have been required. 2) Of \>2 weeks due to nonhematologic toxicities.
| Participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 During Cycle 1 | 0 | 0 | 0 | 1 |
| Participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Abnormal Laboratory Values | 0 | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1 | 253 ± 37.6 | 410 ± 45.5 | 67.0 ± 5.9 | 160 ± 25.7 |
| ng/mL | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5 | 252 ± 9.9 | 453 ± 38.7 | 76.1 ± 17.6 | 170 ± 33.7 |
| hour*nanogram per milliliter (h*ng/mL) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| AUC(0-tau): Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5 | 1515 ± 9.1 | 2163 ± 25.7 | 647 ± 41.3 | 1224 ± 14.9 |
| liter per hour | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 1 | 24.1 ± 20.1 | 32.6 ± 41.7 | 22.8 ± 48.8 | 28.4 ± 23.9 |
| liter per hour | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| CL: Total Clearance for Pevonedistat When Administered Alone and in Combination With Azacitidine on Cycle 1 Day 5 | 24.0 ± 23.0 | 34.8 ± 34.6 | 28.1 ± 38.3 | 28.9 ± 23.7 |
ORR for AML was defined as the percentage of participants with a complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR) based on Modified International Working Group (IWG) Response Criteria for AML. CR was defined as participant achieved the morphologic leukemia-free state and had an absolute neutrophil count (ANC) of more than 1,000 per microliter (/mcL) and platelets of greater than or equal to (\>=) 100,000/mcL. A morphologic leukemia-free state requires less than (\<) 5 percent (%) blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CRi was, after chemotherapy, some participants who fulfilled all of the criteria for CR except for residual neutropenia (\<1,000/mcL) or thrombocytopenia (\<100,000/mcL). PR designation required all the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to between 5% and 25% in the bone marrow aspirate.
| percentage of participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Overall Response Rate (ORR) for Participants With AML | 0 | 0 | 50 | 80 |
ORR for MDS: Percentage of participants with CR,PR or hematologic improvement(HI) based on IWG Response Criteria. CR: BM:\<=5% myeloblasts with normal maturation of all cell lines; persistent dysplasia noted peripheral blood: hemoglobin (Hgb)\>=11 gram per deciliter (g/dL),platelets\>=100\*10\^9/L,neutrophils \>=1.0\*10\^9/L, blasts 0%. PR:CR criteria if abnormal before treatment except: BM blasts decreased by \>=50% from pretreatment but still\>5%; cellularity, morphology not relevant. HI criteria: Erythroid response:Hgb up by \>=1.5 g/dL; transfused RBC reduced by at least 4 red blood cell (RBC) transfusions/8 weeks comparatively last 8 weeks; Platelet response: Increase of \>=30\*10\^9/L for participants starting with \>20\*10\^9/L platelets; increase from \<20\*10\^9/L to \>20\*10\^9/L and by 100%; Neutrophil response: At least 100% and absolute increase \>0.5\*10\^9/L; Progression/relapse after HI: Granulocytes/platelets decreased by 50% from maximum; Hgb reduced by \>=1.5 g/dL; transfusion dependence.
| percentage of participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| ORR for Participants With MDS | — | 0 | 100 | 0 |
CR was defined as participant achieved the morphologic leukemia-free state and had an ANC of more than 1,000/mcL and platelets of \>=100,000/mcL. A morphologic leukemia-free state requires \<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells. CR assessment was based on IWG Response Criteria.
| percentage of participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Percentage of Participants With CR for Participants With AML | 0 | 0 | 50 | 0 |
CR was defined as participant with bone marrow: less than or equal to (\<=) 5% myeloblasts with normal maturation of all cell lines; persistent dysplasia was noted peripheral blood: Hgb \>=11 g/dL, platelets \>=100\*10\^9/L, neutrophils \>=1.0\*10\^9 per liter (/L), blasts 0%. CR assessment was based on IWG Response Criteria.
| percentage of participants | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Percentage of Participants With CR for Participants With MDS | — | 0 | 0 | 0 |
Collected over TEAEs were adverse events that started after first dose through 30 days after the last dose of study drug: single agent arms (up to Cycle 19 [up to Day 429]) (Cycle=21 days); combination arms (up to Cycle 65 [up to Day 1850]) (Cycle=28 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Single Agent Arm: Pevonedistat 25 mg/m^2 | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Single Agent Arm: Pevonedistat 44 mg/m^2 | 2/7 (28.6%) | 7/7 (100%) | 7/7 (100%) |
| Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^2 | 1/3 (33.3%) | 3/3 (100%) | 3/3 (100%) |
| Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 | 1/10 (10%) | 6/10 (60%) | 10/10 (100%) |
| Event | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 5/7 | 2/3 | 1/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 3/7 | 0/3 | 0/10 |
| Arthritis bacterialInfections and infestations | 0/3 | 0/7 | 1/3 | 0/10 |
| Bronchopulmonary aspergillosisInfections and infestations | 1/3 | 0/7 | 0/3 | 0/10 |
| CellulitisInfections and infestations | 0/3 | 0/7 | 1/3 | 0/10 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/7 | 1/3 | 0/10 |
| Septic shockInfections and infestations | 0/3 | 0/7 | 1/3 | 0/10 |
| Urinary tract infectionInfections and infestations | 0/3 | 0/7 | 1/3 | 0/10 |
| Anal abscessInfections and infestations | 0/3 | 0/7 | 0/3 | 2/10 |
| Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 1/7 | 0/3 | 0/10 |
| Event | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2 + Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2 |
|---|---|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 0/7 | 3/3 | 4/10 |
| ConstipationGastrointestinal disorders | 1/3 | 3/7 | 2/3 | 7/10 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/7 | 2/3 | 2/10 |
| Alanine aminotransferase increasedInvestigations | 1/3 | 0/7 | 2/3 | 3/10 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/7 | 2/3 | 3/10 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 1/7 | 2/3 | 3/10 |
| Decreased appetiteMetabolism and nutrition disorders | 0/3 | 0/7 | 2/3 | 0/10 |
| FatigueGeneral disorders | 1/3 | 2/7 | 2/3 | 1/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/3 | 4/7 | 0/3 | 3/10 |
| HypokalaemiaMetabolism and nutrition disorders | 0/3 | 2/7 | 2/3 | 3/10 |
Safety population was defined as all enrolled participants who received at least 1 dose of any study drug, pevonedistat or azacitidine.
| Age, Continuous(years) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| Mean | 78.0 ± 5.20 | 69.0 ± 11.27 | 65.0 ± 9.54 | 64.9 ± 8.52 | 67.9 ± 9.72 |
| Sex: Female, Male(Participants) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| Female | 1 | 0 | 0 | 3 | 4 |
| Male | 2 | 7 | 3 | 7 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 7 | 3 | 10 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 7 | 3 | 10 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| Japan | 2 | 2 | 1 | 7 | 12 |
| Korea, South | 1 | 2 | 0 | 1 | 4 |
| Taiwan | 0 | 3 | 2 | 2 | 7 |
| Body Surface Area (BSA)(square meter (m^2)) | Single Agent Arm: Pevonedistat 25 mg/m^2 | Single Agent Arm: Pevonedistat 44 mg/m^2 | Combination Arm: Pevonedistat 10 mg/m^2+ Azacitidine 75 mg/m^2 | Combination Arm: Pevonedistat 20 mg/m^2+ Azacitidine 75 mg/m^2 | Total |
|---|---|---|---|---|---|
| Mean | 1.5 ± 0.26 | 1.7 ± 0.21 | 1.7 ± 0.04 | 1.7 ± 0.18 | 1.7 ± 0.20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2016 to primary completion in Jan 2022, 68 months.
Results were first posted in Nov 2023, 1 year 9 months after primary completion.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's 68 months is above that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pevonedistat · Azacitidine
Millennium Pharmaceuticals, Inc. →